Your browser doesn't support javascript.
loading
Evaluation of Poly(I:C) and combination of CpG ODN plus Montanide ISA adjuvants to enhance the efficacy of outer membrane vesicles as an acellular vaccine against Brucella melitensis infection in mice.
Golshani, Maryam; Amani, Mona; Amirzadeh, Fatemeh; Nazeri, Elahe; Davar Siadat, Seyed; Nejati-Moheimani, Mehdi; Arsang, Amin; Bouzari, Saeid.
Afiliación
  • Golshani M; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
  • Amani M; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
  • Amirzadeh F; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
  • Nazeri E; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
  • Davar Siadat S; Tuberculosis and Pulmonary Research Department, Pasteur Institute of Iran, Tehran, Iran.
  • Nejati-Moheimani M; Bacterial Vaccine and Antigen Production Branch, Pasteur Institute of Iran, Karaj, Iran.
  • Arsang A; Bacterial Vaccine and Antigen Production Branch, Pasteur Institute of Iran, Karaj, Iran.
  • Bouzari S; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran. Electronic address: bouzari@pasteur.ac.ir.
Int Immunopharmacol ; 84: 106573, 2020 Jul.
Article en En | MEDLINE | ID: mdl-32454410
Brucellosis is the most common zoonotic disease worldwide and still there is no vaccine for human use. The commercial animal vaccines also have major problems that limit their use. Therefore, there is a need for an effective Brucella vaccine which is multivalent and produces a good protective immunity with minimal disadvantages. Due to their heterogeneous composition and diverse functions, OMVs are promising acellular vaccine candidates against brucellosis. In the present study, the potential of Poly(I:C) or CpG ODN 1826+ Montanide ISA 70 VG adjuvant formulations were evaluated to enhance the immunity and protection levels conferred by OMVs against Brucella challenge in mice. The results indicated that both vaccine regimens were able to induce strong Th1-biased responses and confer protective levels significantly higher than REV.1 live vaccine. With regard to the results, it is concluded that OMVs in either adjuvant can be introduced as a new vaccine candidate against B. melitensis infection.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligodesoxirribonucleótidos / Brucelosis / Vacuna contra la Brucelosis / Ácidos Oléicos / Adyuvantes Inmunológicos / Poli I-C / Estructuras de la Membrana Celular / Membrana Externa Bacteriana / Manitol Límite: Animals Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligodesoxirribonucleótidos / Brucelosis / Vacuna contra la Brucelosis / Ácidos Oléicos / Adyuvantes Inmunológicos / Poli I-C / Estructuras de la Membrana Celular / Membrana Externa Bacteriana / Manitol Límite: Animals Idioma: En Revista: Int Immunopharmacol Asunto de la revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Países Bajos